From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD3 receptor
Clinical data
Chemical data
 YesY (what is this?)  (verify)

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.[1]

PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.[2] Nevertheless, clinical trials continue for various diseases like multiple myeloma[3] and diabetes mellitus type 1[4][5] as of July 2009.

Visilizumab has also been radiolabelled with technetium-99m for imaging T cells.[6]


  1. ^ "PDL BioPharma, Development Pipeline - Nuvion (visilizumab)". Archived from the original on 2007-09-15. Retrieved 2008-02-11. 
  2. ^ "PDL Lands in a Hazard". Retrieved 2009-05-27. 
  3. ^ "Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma". Retrieved 2010-03-15. 
  4. ^ Kaufman, A; Herold, KC (2009). "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/metabolism research and reviews 25 (4): 302–6. doi:10.1002/dmrr.933. PMID 19319985. 
  5. ^ "Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes". 
  6. ^ Malviya, G; D'alessandria, C; Bonanno, E; Vexler, V; Massari, R; Trotta, C; Scopinaro, F; Dierckx, R; Signore, A (2009). "Radiolabeled Humanized Anti-CD3 Monoclonal Antibody Visilizumab for Imaging Human T-Lymphocytes". Journal of Nuclear Medicine 50 (10): 1683–91. doi:10.2967/jnumed.108.059485. PMID 19759100.